Moleculin Completes Part A Enrollment in MIRACLE Trial

Moleculin said enrollment in Part A of its Phase 2/3 MIRACLE trial of Annamycin plus HiDAC in relapsed or refractory AML is complete. A full 90-patient Part A data readout is expected in Q1 2027, pending financing; the company described interim efficacy as encouraging.